文献速递消化道肿瘤放疗放疗物理与技术

食管癌质子放疗与光子放疗的4级淋巴细胞减少比较

A Comparison of Grade 4 Lymphopenia With Proton Versus Photon Radiation Therapy for Esophageal Cancer.
PubMed 文献 · Adv Radiat Oncol · 2019-01-17

该研究比较食管癌根治性放疗同步化疗中质子放疗(PRT)与光子放疗(XRT)的4级淋巴细胞减少(G4L)发生率。144例患者中,XRT组G4L发生率为56%,PRT组为22%(P < .01);多因素分析显示XRT与G4L相关(OR 5.13;95%CI 2.35-11.18;P < .001)。倾向性匹配队列中XRT组G4L发生率为60%,PRT组为24%。

要点

  • 食管癌根治性放疗同步化疗中,XRT组G4L发生率56%高于PRT组22%(P < .01)
  • 多因素分析显示XRT(OR 5.13;95%CI 2.35-11.18;P < .001)与G4L相关
  • 倾向性匹配队列中XRT组G4L发生率60%高于PRT组24%

核心结论

  • 与PRT相比,XRT与G4L风险显著升高相关。
  • 需进一步研究评估放疗方式与抗肿瘤免疫及长期结局之间的潜在关联。

研究设计与样本

  • 研究纳入接受根治性放疗同步化疗的食管癌患者144例,其中XRT组79例(27%为三维适形放疗,73%为调强放疗),PRT组65例(100%为笔束扫描)。
  • G4L定义为放疗期间绝对淋巴细胞计数最低值<200/mm3。
  • 采用单因素和多因素逻辑回归分析评估与淋巴细胞减少相关的患者和治疗因素,并构建倾向性匹配队列。

主要发现

  • XRT组G4L发生率为56%,PRT组为22%,差异显著(P < .01)。
  • 多因素分析中,XRT(OR 5.13;95%CI 2.35-11.18;P < .001)和III/IV期(OR 4.54;95%CI 1.87-11.00;P < .001)与G4L相关。
  • 倾向性匹配队列包含PRT组50例和XRT组50例,XRT组G4L发生率为60%,PRT组为24%。
  • 匹配队列多因素分析中,XRT(OR 5.28;95%CI 2.14-12.99;P < .001)和III/IV期(OR 3.77;95%CI 1.26-11.30;P = .02)与G4L相关。

关键数值与推荐

  • G4L定义为放疗期间绝对淋巴细胞计数最低值<200/mm3。
  • XRT组G4L发生率56% vs PRT组22%(P < .01)。
  • 多因素分析XRT的OR为5.13(95%CI 2.35-11.18;P < .001),III/IV期的OR为4.54(95%CI 1.87-11.00;P < .001)。
  • 倾向性匹配队列中XRT组G4L发生率60% vs PRT组24%;XRT的OR为5.28(95%CI 2.14-12.99;P < .001),III/IV期的OR为3.77(95%CI 1.26-11.30;P = .02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需进一步研究评估放疗方式与抗肿瘤免疫及长期结局之间的潜在关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Grade 4 lymphopenia (G4L) during radiation therapy (RT) is associated with higher rates of distant metastasis and decreased overall survival in a number of malignancies, including esophageal cancer (EC). Through a reduction in integral radiation dose, proton RT (PRT) may reduce G4L relative to photon RT (XRT). The purpose of this study was to compare G4L in patients with EC undergoing PRT versus XRT. METHODS AND MATERIALS: Patients receiving curative-intent RT and concurrent chemotherapy for EC were identified. Lymphocyte nadir was defined as the lowest lymphocyte count during RT. G4L was defined as absolute lymphocyte count <200/mm3. Univariate and multivariable logistic regression analyses (MVA) were performed to assess patient and treatment factors associated with lymphopenia. A propensity-matched (PM) cohort was created using logistic regression, including baseline covariates. RESULTS: A total of 144 patients met the inclusion criteria. The median age was 66 years (range, 32-85 years). Of these patients, 79 received XRT (27% 3-dimensional chemo-RT and 73% intensity modulated RT) and 65 received PRT (100% pencil-beam scanning). Chemotherapy consisted of weekly carboplatin and paclitaxel (99%). There were no significant differences in baseline characteristics between the groups, except for age (median 4 years older in the PRT cohort). G4L was significantly higher in patients who received XRT versus those who received PRT (56% vs 22%; P < .01). On MVA, XRT (odds ratio [OR]: 5.13; 95% confidence interval [CI], 2.35-11.18; P < .001) and stage III/IV (OR: 4.54; 95% CI, 1.87-11.00; P < .001) were associated with G4L. PM resulted in 50 PRT and 50 XRT patients. In the PM cohort, G4L occurred in 60% of patients who received XRT versus 24% of patients who received PRT. On MVA, XRT (OR: 5.28; 95% CI, 2.14-12.99; P < .001) and stage III/IV (OR: 3.77; 95% CI, 1.26-11.30; P = .02) were associated with G4L. CONCLUSIONS: XRT was associated with a significantly higher risk of G4L in comparison with PRT. Further work is needed to evaluate a potential association between RT modality and antitumor immunity as well as long-term outcomes.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Routman DM, Garant A, Lester SC, et al. A Comparison of Grade 4 Lymphopenia With Proton Versus Photon Radiation Therapy for Esophageal Cancer. Adv Radiat Oncol. 2019. PMID: 30706012. doi:10.1016/j.adro.2018.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。